Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.53 |
| ▸ | JAK1 | P23458 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | XIAP | P98170 | 1/20 | 0.42 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6159410 | 1.00 | JAK2 (0.53) | JAK2JAK1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL6159416 | 1.00 | JAK2 (0.53) | JAK2JAK1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL21143479 | 0.85 | SMN1; SMN2 (0.54) | JAK2JAK1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL30960033 | 0.84 | JAK2 (0.61) | JAK2JAK1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL30959962 | 0.84 | JAK2 (0.61) | JAK2JAK1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL26100843 | 0.84 | GPR119 (0.61) | JAK2JAK1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL30960004 | 0.84 | JAK2 (0.61) | JAK2JAK1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL30965696 | 0.84 | GPR119 (0.61) | JAK2JAK1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL26101361 | 0.84 | GPR119 (0.61) | JAK2JAK1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL26101527 | 0.84 | GPR119 (0.61) | JAK2JAK1SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949662-B2 | Cis-substituted aminocyclopropane derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-27 | — | — | US | disclosed |
| EP-0919553-B1 | cis-SUBSTITUTED AMINOCYCLOPROPANE DERIVATIVES | DAIICHI SEIYAKU CO (JP) | 2005-03-02 | — | — | EP | disclosed |
| US-20020183523-A1 | Cis-substituted aminocyclopropane derivative | DAIICHI PHARMACEUTICAL CO., LTD | 2002-12-05 | — | — | US | disclosed |
| US-6462040-B1 | MICROBIOCIDES; BACTERIOCIDES; ANTIPROTOZOA AGENTS; QUINOLONE ANTIBIOTICS; SIDE EFFECT REDUCTION; ANTIBIOTIC-RESISTANT BACTERIA INCLUDING STAPHYLOCCOCUS; VETERINARY MEDICINE | DAIICHO PHARMACEUTICAL CO., LTD. (JP) | 2002-10-08 | — | — | US | disclosed |
| US-6391889-B2 | POTENT ANTIMICROBIAL ACTIVITY ON BROAD RANGE OF MICROORGANISMS, E.G., STAPHYLOCOCCUS, GRAMPOSITIVE BACTERIA AND QUINOLONE ANTIBIOTIC RESISTANCE; SIDE EFFECT REDUCTION; NONTOXIC | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-05-21 | — | — | US | disclosed |
| US-20020052502-A1 | Cis-substituted aminocyclopropane derivative | DAIICHI PHARMACEUTICAL CO., LTD. | 2002-05-02 | — | — | US | disclosed |
| US-20020002182-A1 | CIS-SUBSTITUTED AMINOCYCLOPROPANE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-01-03 | — | — | US | disclosed |
| EP-0919553-A1 | cis-SUBSTITUTED AMINOCYCLOPROPANE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052502-A1 | Cis-substituted aminocyclopropane derivative | SLC11A2, MYD88, ARG1 | JAK2 3101/4885JAK1 3801/4885SMN1; SMN2 3810/4885 |
| US-20020002182-A1 | CIS-SUBSTITUTED AMINOCYCLOPROPANE DERIVATIVES | PHOSPHO1, CCR2, ECH1 | JAK2 3401/4885JAK1 4119/4885SMN1; SMN2 4640/4885 |
| US-20020183523-A1 | Cis-substituted aminocyclopropane derivative | SLC11A2, MYD88, ARG1 | JAK2 3101/4885JAK1 3801/4885SMN1; SMN2 3810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.